Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06418126
NA

Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer

Sponsor: Centre Paul Strauss

View on ClinicalTrials.gov

Summary

Recurrence of triple-negative breast cancer (TNBC) occurs in around 30% of patients within 3 years of treatment. For some TNBC patients, recurrence occurs on average 2.6 years after treatment, while for others recurrence does not occur early. TNBC patients can therefore be divided into two groups: those with early recurrence and those who respond well to treatment. At present, there are no biomarkers to differentiate these two groups. Some studies suggest that radiation-induced inflammatory cytokines may stimulate the development of new metastases. Gene expression profiling or protein signatures have not been able to define such biomarkers. The aim of this research protocol is to recruit patients to evaluate if the elevation of the cytokines IL-1β, IL-5 and IL-6 in plasma collected during radiotherapy can be used to predict TNBC patients at high risk of recurrence.

Official title: Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer : TNBC-RT2023

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2024-01-11

Completion Date

2030-08-19

Last Updated

2026-01-05

Healthy Volunteers

No

Interventions

BIOLOGICAL

blood sampling before radiotherapy

A blood sample (20 ml) will be taken prior to radiotherapy

BIOLOGICAL

blood sampling after the fourth radiotherapy session

A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.

OTHER

collection of acute toxicity (radiodermatitis)

for the entire duration of radiotherapy

OTHER

collection of late toxicity

every year for 5 years

OTHER

collection of disease status

throughout the study

RADIATION

Radiotherapy - Breast +/- lymph node areas

40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week

RADIATION

Radiotherapy - Boost operating bed

10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week

Locations (1)

Institut de cancérologie Strasbourg europe

Strasbourg, France